Clinical Trial Goal
To find out:
- The highest dose of BH-30236 that's safe to give with or without venetoxlax
- If BH-30236 is safe and works well to treat AML or high-risk MDS that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have one of the following that has relapsed or is refractory:
- AML
- MDS that doctors consider to be high-risk
- Do not have any of the following:
- Acute promyelocytic leukemia
- Chronic myeloid leukemia (CML) with blast crisis. Your doctor can tell you this
- Have not been treated with a drug that targets CLK. Your doctor can tell you this
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 3 months
- Do not have graft-versus-host-disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
BH-30236 is a small molecule inhibitor that targets CLK on certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
In this trial, you'll be placed in 1 of 2 groups. Once placed, you’ll be told what group you're in:
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
In this trial, you'll be placed in 1 of 2 groups. Once placed, you’ll be told what group you're in:
- Group 1 – BH-30236
- Group 2 – BH-30236 plus venetoclax
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- BH-30236 – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Venetoclax - A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has not yet approved BH-30236.
Locations
Sponsors
lead: BlossomHill Therapeutics
